Gastrointestinal stromal tumors: A single institution experience of 50 cases

Indian Journal of Gastroenterology

Volumn 26, Issue 5, 2007, Pages 225-229

  Rajappa, Senthil ^a,b   Muppavarapu, Krishna Mohan ^a   Uppin, Shantveer ^a   Digumarti, Raghunadharao ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^b Department of Medical Oncology ^*

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STOMACH TUMOR; TREATMENT DURATION; TUMOR DIAGNOSIS; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 39049141170     PISSN: 02548860     EISSN: 02548860     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005;104:1781-8.
2. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-9.
3. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005;103:821-9.
4. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
5. Benjamin RS, Blanke CD, Blay J, Bonvalot S, Eisenberge B. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist 2006;11:9-20.
6. Cohen MH, Dagher R, Griebel DJ, Ibrahim A, Martin A, Scher SN, et al. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist 2002;7:393-400.
7. Mudan SS, Conlon KC, Woodruff J, Lewis J, Brennan MF. Salvage surgery in recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000;88:51-8.
8. Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.
9. Lamba M, Mukherjee G, Saini KS, Ramachandra C, Rao C, Kumar R, et al. Clinico-pathologic pattern of gastrointestinal stromal tumors (GIST) in southern India: A single institution experience (Abstract). J Clin Oncol 2007;25 (18S):20531.
10. Bakshi CA, Jain RA, Sastry PSRK, Sainani AR, Advani SH. Imatinib in gastrointestinal stromal tumors. J Assoc Physicians India 2004;52:403-9.
11. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
12. Verweij J, Casali PJ, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, et al. Progression free survival in patients with gastrointestinal stromal tumors treated with high dose imatinib: a randomized study. Lancet 2004;364:1127-34.
13. Demetri D G, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts Pje. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
14. Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extra gastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000;13:577-85.
15. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
16. Van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38 (Suppl 5): S83-S87.
17. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose randomized study of imatinib mesylate (STI571) for GIST: intergroup S0033 early results [abstract 3271]. Proc Am Soc Clin Oncol 2003;22:814S.
18. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression (Abstract). J Clin Oncol 2006;24 (18S):9506.
19. Lopez-Pousa A, Gallego O, Matias-Guiu X, Nadal R, Villanueva R, Quintana M, et al. Clinical prognostic factors in metastatic gastrointestinal stromal tumors (GIST) patients treated with imatinib (Abstract). J Clin Oncol 2006;24(18S):19500.
20. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
21. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68-77.
22. Van Glabbeke M, Owzar K, Rankin C, Simes J, Crowley J, GIST meta-analysis group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients (Abstract). J Clin Oncol 2007;25(18S):10004.